- Larger drugmakers are eyeing $7.6 billion company: sources
- Global health-care dealmaking has remained robust this year
Apellis Pharmaceuticals Inc., a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers, people with knowledge of the matter said.
The company is speaking to advisers to consider its options amid the interest, they said. Apellis may also consider seeking partnerships or licensing agreements for some of its ophthalmology products, the people said, asking not to be identified discussing confidential information.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.